收稿日期: 2020-02-28
网络出版日期: 2022-07-14
陈施吾, 窦荣花, 王玉凯, 王含, 王晓平, 陈先文, 陈玲, 王训, 屈洪党, 陈生弟, Susan Fox, 李燕, 王刚 . 帕金森病血压管理专家共识[J]. 诊断学理论与实践, 2020 , 19(05) : 460 -468 . DOI: 10.16150/j.1671-2870.2020.05.004
[1] | Klanbut S, Phattanarudee S, Wongwiwatthananukit S, et al. Symptomatic orthostatic hypotension in Parkinson’s disease patients: prevalence, associated factors and its impact on balance confidence[J]. J Neurol Sci, 2018, 385: 168-174. |
[2] | Espay AJ, LeWitt PA, Hauser RA, et al. Neurogenic orthostatic hypotension and supine hypertension in Parkinson’s disease and related synucleinopathies: prioritisation of treatment targets[J]. Lancet Neurol, 2016, 15(9): 954-966. |
[3] | Allcock LM, Ullyart K, Kenny RA, et al. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry, 2004, 75(10): 1470-1471. |
[4] | Senard JM, Raï S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry, 1997, 63(5): 584-589. |
[5] | Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment[J]. J Am Coll Cardiol, 2015, 66(7): 848-860. |
[6] | Palma JA, Kaufmann H. Orthostatic hypotension in Parkinson disease[J]. Clin Geriatr Med, 2020, 36(1): 53-67. |
[7] | Umehara T, Matsuno H, Toyoda C, et al. Clinical characteristics of supine hypertension in de novo Parkinson di-sease[J]. Clin Auton Res, 2016, 26(1): 15-21. |
[8] | Tadic M, Cuspidi C, Pencic-Popovic B, et al. The influe-nce of night-time hypertension on left ventricular mechanics[J]. Int J Cardiol, 2017, 243: 443-448. |
[9] | Di Stefano C, Sobrero G, Milazzo V, et al. Cardiac organ damage in patients with Parkinson’s disease and reverse dipping[J]. J Hypertens, 2020, 38(2): 289-294. |
[10] | Chatzistamatiou EI, Moustakas GN, Veioglanis S, et al. Nocturnal hypertension: poor correlation with office blood pressure but strong prognostic factor for target organ damage[J]. Hellenic J Cardiol, 2012, 53(4): 263-272. |
[11] | Baker J, Kimpinski K. Management of supine hypertension complicating neurogenic orthostatic hypotension[J]. CNS Drugs, 2017, 31(8): 653-663. |
[12] | Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension[J]. J Hypertens, 2018, 36(10): 1953-2041. |
[13] | 王刚, 崔海伦. 帕金森病临床诊断和治疗现状及进展[J]. 重庆医科大学学报, 2019, 44(4): 86-89. |
[14] | 中国高血压防治指南修订委员会, 高血压联盟(中国)中华医学会心血管病学分会, 中国医师协会高血压专业委员会, 中国医疗保健国际交流促进会高血压分会, 中国老年医学学会高血压分会. 中国高血压防治指南(2018年修订版)[J]. 心脑血管病防治, 19(1): 1-44. |
[15] | 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第三版)[J]. 药学与临床研究, 2014, 27(4): 428-433. |
[16] | Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome[J]. Auton Neurosci, 2011, 161(1-2): 46-48. |
[17] | Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in older adults[J]. Hypertension, 1992, 19(6 Pt 1): 508-519. |
[18] | Velseboer DC, De Haah RJ, Wieling W, et al. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis[J]. Parkinsonism Relat Disord, 2011, 17(10): 724-729. |
[19] | Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go?[J]. Mov Disord, 2015, 30(5): 639-645. |
[20] | Kaufmann H, Palma JA. Neurogenic orthostatic hypotension: the very basics[J]. Clin Auton Res, 2017, 27 Suppl 1: 39-43. |
[21] | Krediet CT, Van Lieshout JJ, Bogert LW, et al. Leg crossing improves orthostatic tolerance in healthy subjects: a placebo-controlled crossover study[J]. Am J Physiol Heart Circ Physiol, 2006, 291(4): H1768-H1772. |
[22] | Goldstein DS, Cheshire WP. Beat-to-beat blood pressure and heart rate responses to the valsalva maneuver[J]. Clin Auton Res, 2017, 27(6): 361-367. |
[23] | Diedrich A, Biaggioni I. Segmental orthostatic fluid shifts[J]. Clin Auton Res, 2004, 14(3): 146-147. |
[24] | Schdreglmann SR, Büchele F, Sommerauer M, et al. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson’s disease[J]. Eur J Neurol, 2017, 24(4): 545-551. |
[25] | Hoehn MM. Levodopa-induced postural hypotension. Treatment with fludrocortisone[J]. Arch Neurol, 1975, 32(1): 50-51. |
[26] | Sandroni P, Benarroch EE, Wijdicks EF. Caudate hemorrhage as a possible complication of midodrine-induced supine hypertension[J]. Mayo Clin Proc, 2001, 76(12): 1275. |
[27] | Kaufmann H, Brannan T, Krakoff L, et al. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine)[J]. Neurology, 1988, 38(6): 951-956. |
[28] | Byun JI, Moon J, Kim DY, et al. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension[J]. Neurology, 2017, 89(10): 1078-1086. |
[29] | Coll M, Rodriguez S, Raurell I, et al. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats[J]. Hepatology, 2012, 56(5): 1849-1860. |
[30] | Hauser RA, Biaggioni I, Hewitt LA, et al. Integrated analysis of droxidopa for the treatment of neurogenic orthostatic hypotension in patients with Parkinson disease[J]. Mov Disord Clin Pract, 2018, 5(6): 627-634. |
[31] | Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure[J]. Hypertension, 2014, 64(6): 1235-1240. |
[32] | Okamoto LE, Shibao CA, Gamboa A, et al. Synergistic pressor effect of atomoxetine and pyridostigmine in patients with neurogenic orthostatic hypotension[J]. Hypertension, 2019, 73(1): 1235-1241. |
[33] | 金兆清, 薛越, 刘长林, 等. 中药升压汤治疗慢性低血压病效果观察[J]. 解放军预防医学杂志, 2010, 28(1): 78. |
[34] | Grijalva CG, Biaggioni I, Griffin MR, et al. Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension[J]. J Am Heart Assoc, 2017, 6(10): e006848. |
[35] | Smith W, Wan H, Much D, et al. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study[J]. Clin Auton Res, 2016, 26(4): 269-277. |
[36] | Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B)[J]. Mov Disord, 2015, 30(5): 646-654. |
[37] | Pérez-Lloret S, Quarracino C, Otero-Losada M, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial[J]. Expert Opin Pharmacother, 2019, 20(6): 635-645. |
[38] | Hale GM, Brenner M. Atomoxetine for orthostatic hypotension in an elderly patient over 10 weeks: a case report[J]. Pharmacotherapy, 2015, 35(9): e141-e148. |
[39] | Jordan J, Tank J, Heusser K, et al. What do we really know about supine hypertension in patients with orthostatic hypotension[J]. Curr Opin Cardiol, 2019, 34(4): 384-389. |
[40] | Goldstein DS, Pechnik S, Holmes C, et al. Association between supine hypertension and orthostatic hypotension in autonomic failure[J]. Hypertension, 2003, 42(2): 136-142. |
[41] | Biaggioni I, Robertson RM. Hypertension in orthostatic hypotension and autonomic dysfunction[J]. Cardiol Clin, 2002, 20(2): 291-301. |
[42] | Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease[J]. J Neurol Sci, 2011, 310(1-2): 123-128. |
[43] | Pathak A, Senard JM. Blood pressure disorders during Parkinson’s disease: epidemiology, pathophysiology and management[J]. Expert Rev Neurother, 2006, 6(8): 1173-1180. |
[44] | 李华, 李锐洁. 老年人体位性低血压合并卧位高血压[J]. 中华高血压杂志, 2007, 15(4): 346-349. |
[45] | 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 血管紧张素转换酶抑制剂在心血管病中应用中国专家共识[J]. 中华心血管病杂志, 2007, 35(2): 97-106. |
[46] | Kooner JS, Raimbach S, Bannister R, et al. Angiotensin converting enzyme inhibition lowers blood pressure in patients with primary autonomic failure independently of plasma renin levels and sympathetic nervous activity[J]. J Hypertens Suppl, 1989, 7(6): S42-S43. |
[47] | Arnold AC, Okamoto LE, Gamboa A, et al. Angiotensin Ⅱ, independent of plasma renin activity, contributes to the hypertension of autonomic failure[J]. Hypertension, 2013, 61(3): 701-706. |
[48] | Okamoto LE, Gamboa A, Shibao CA, et al. Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension[J]. Hypertension, 2014, 64(6): 1241-1247. |
[49] | Shibao CA, Kaufmann H. Pharmacotherapy of cardiovascular autonomic dysfunction in Parkinson disease[J]. CNS Drugs, 2017, 31(11): 975-989. |
[50] | Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies[J]. Mov Disord, 2018, 33(3): 372-390. |
[51] | Jordan J, Shannon JR, Pohar B, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure[J]. J Am Soc Nephrol, 1999, 10(1): 35-42. |
[52] | Luciano GL, Brennan MJ, Rothberg MB. Postprandial hypotension[J]. Am J Med, 2010, 123(3): 281. |
[53] | Pavelic A, Krbot Skoric M, Crnošija L, et al. Postprandial hypotension in neurological disorders: systematic review and meta-analysis[J]. Clin Auton Res, 2017, 27(4): 263-271. |
[54] | Uumhara T, Nnakahara A, Matsuno H, et al. Predictors of postprandial hypotension in elderly patients with de novo Parkinson’s disease[J]. J Neural Transm (Vienna), 2016, 123(11): 1331-1339. |
[55] | Jansen RW, Peeters TL, Lenders JW, et al. Somatostatin analog octreotide (SMS 201-995) prevents the decrease in blood pressure after oral glucose loading in the elderly[J]. J Clin Endocrinol Metab, 1989, 68(4): 752-756. |
[56] | Hoeldtke RD, O’Dorisio TM, Boden G. Treatment of autonomic neuropathy with a somatostatin analogue SMS-201-995[J]. Lancet, 1986, 2(8507): 602-605. |
[57] | Shibao C, Gamboa A, Diedrich A, et al. Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure[J]. Hypertension, 2007, 50(1): 54-61. |
[58] | Jian ZJ, Zhou BY. Efficacy and safety of acarbose in the treatment of elderly patients with postprandial hypotension[J]. Chin Med J (Engl), 2008, 121(20): 2054-2059. |
[59] | Maruta T, Komai K, Takamori M, et al. Voglibose inhibits postprandial hypotension in neurologic disorders and elderly people[J]. Neurology, 2006, 66(9): 1432-1434. |
[60] | Noack C, Schroeder C, Heusser K, et al. Cardiovascular effects of levodopa in Parkinson’s disease[J]. Parkinsoni-sm Relat Disord, 2014, 20(8): 815-818. |
[61] | Wilson JA, Smith RG. The prevalence and aetiology of long-term L-dopa side-effects in elderly Parkinsonian patients[J]. Age Ageing, 1989, 18(1): 11-16. |
[62] | Churchyard A, Mathias CJ, Lees AJ. Selegiline-induced postural hypotension in Parkinson’s disease: a longitudinal study on the effects of drug withdrawal[J]. Mov Disord, 1999, 14(2): 246-251. |
[63] | Corder CN, Kanefsky TM, McDonald RH Jr, et al. Postural hypotension: adrenergic responsivity and levodopa therapy[J]. Neurology, 1977, 27(10): 921-927. |
[64] | Lokhandwala MF, Barrett RJ. Dopamine receptor agonist in cardiovascular therapy[J]. Drug Dev Res, 3(4): 299-310. |
[65] | 温洪波, 张振馨, 罗毅, 等. 普拉克索治疗帕金森病的多中心、随机、双盲、溴隐亭对照临床疗效和安全性研究[J]. 中华神经科杂志, 2006, 39(9): 604-608. |
[66] | Montastruc JL, Chaumerliac C, Desboeuf K, et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database[J]. Clin Neuropharmacol, 2000, 23(5): 271-275. |
[67] | Bhattacharya KF, Nouri S, Olanow CW, et al. Selegiline in the treatment of Parkinson’s disease: its impact on orthostatic hypotension[J]. Parkinsonism Relat Disord, 2003, 9(4): 221-224. |
[68] | Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease[J]. Drugs, 2000, 59(6): 1233-1250. |
[69] | Teychenne PF, Calne DB, Lewis PJ, et al. Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase[J]. Clin Pharmacol Ther, 1975, 18(3): 273-277. |
[70] | Rose LM, Ohlinger MJ, Mauro VF. A hypertensive reaction induced by concurrent use of selegiline and dopamine[J]. Ann Pharmacother, 2000, 34(9): 1020-1024. |
/
〈 |
|
〉 |